Sciencepulse

GLP-1 Drugs Enter a New Chapter as Uses Multiply and Questions Pile Up

Health·November 15, 2026

GLP-1 drugs started out as a way to help people with type 2 diabetes control their blood sugar. The class mimics a gut hormone that boosts insulin release and signals fullness to the brain. Semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro, pushed the drugs into a much bigger role once they proved powerful for weight loss. That shift turned them into some of the most sought-after prescriptions in the world, and the story has only become more tangled since.

On a recent episode of the Scientific American podcast Science Quickly, host Kendra Pierre-Louis and associate health editor Lauren Young traced that arc. Demand for the branded products has outstripped what many patients can easily get, and a fast-growing market for compounded versions has raised hard questions about quality, dosing and safety. Compounded products are made by pharmacies rather than approved by the FDA in the same way, and federal regulators have begun cracking down on how they are marketed and sold.

The science is moving in a different direction at the same time. Researchers are testing GLP-1 drugs for conditions far from diabetes and obesity. One line of work has found that people taking these medications had a lower risk of several kinds of drug and alcohol addiction, which has prompted interest in whether they could help treat substance use. Other studies point to cardiovascular benefits, and scientists are looking at whether the drugs might help with additional conditions as well.

That breadth is the reason the field feels more complicated than it did a few years ago. Each new potential use raises fresh questions about who should take these drugs, for how long, and at what dose. Long-term effects remain an open area of study, and the conversation in the episode makes clear that the answers will shape how doctors and regulators handle these medicines next. For patients and the companies that make them, the next chapter is likely to be defined as much by evidence and oversight as by demand.